Entrectinib in patients with advanced or metastatic NTRK fusion- positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)

被引：0
|
作者：
Doebele, R. C.
Drilon, A.
Paz-Ares, L.
机构：
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E372 / E372
页数：1
相关论文
共 50 条
  • [1] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)
    Doebele, R. C.
    Drilon, A.
    Paz-Ares, A.
    LANCET ONCOLOGY, 2020, 22 (10): : E428 - E428
  • [2] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)
    Doebele, R. C.
    Drilon, A.
    Paz-Ares, L.
    LANCET ONCOLOGY, 2020, 21 (07): : E341 - E341
  • [3] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)
    Doebele, R. C.
    Drilon, A.
    Paz-Ares, L.
    LANCET ONCOLOGY, 2020, 21 (02): : E70 - E70
  • [4] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
    Doebele, Robert C.
    Drilon, Alexander
    Paz-Ares, Luis
    Siena, Salvatore
    Shaw, Alice T.
    Farago, Anna F.
    Blakely, Collin M.
    Seto, Takashi
    Cho, Byung Chul
    Tosi, Diego
    Besse, Benjamin
    Chawla, Sant P.
    Bazhenova, Lyudmila
    Krauss, John C.
    Chae, Young Kwang
    Barve, Minal
    Garrido-Laguna, Ignacio
    Liu, Stephen V.
    Conkling, Paul
    John, Thomas
    Fakih, Marwan
    Sigal, Darren
    Loong, Herbert H.
    Buchschacher, Gary L., Jr.
    Garrido, Pilar
    Nieva, Jorge
    Steuer, Conor
    Overbeck, Tobias R.
    Bowles, Daniel W.
    Fox, Elizabeth
    Riehl, Todd
    Chow-Maneval, Edna
    Simmons, Brian
    Cui, Na
    Johnson, Ann
    Eng, Susan
    Wilson, Timothy R.
    Demetri, George D.
    LANCET ONCOLOGY, 2020, 21 (02): : 271 - 282
  • [5] Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials (vol 21, pg 261, 2020)
    Drilon, A.
    Siena, S.
    Dziadziuszko, R.
    LANCET ONCOLOGY, 2020, 21 (07): : E341 - E341
  • [6] Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials (vol 21, pg 261, 2020)
    Drilon, A.
    Siena, S.
    Dziadziuszko, R.
    LANCET ONCOLOGY, 2020, 21 (02): : E70 - E70
  • [7] Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours
    Bazhenova, L.
    Liu, S. V.
    Lin, J. J.
    Lu, S.
    Drilon, A.
    Chawla, S. P.
    Fakih, M.
    Krzakowski, M.
    Paz-Ares, L.
    Blakely, C.
    Buchschacher, G. L., Jr.
    Cassier, P.
    Fan, Y.
    Folprecht, G.
    McCallum, S.
    Pitcher, B.
    Chen, D.
    Freund, R.
    Springfeld, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S598 - S599
  • [8] Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours
    Lu, S.
    De Braud, F. G. M.
    Fan, Y.
    Hu, X.
    Ohe, Y.
    Yu, Y.
    Ahn, M-J.
    Cassier, P.
    Lin, J. J.
    Paz-Ares, L.
    Xue, C.
    Bordogna, W.
    Patel, S.
    Zeuner, H.
    Dong, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S468 - S469
  • [9] Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors (vol 28, pg 1302, 2022)
    Demetri, George D.
    De Braud, Filippo
    Drilon, Alexander
    Siena, Salvatore
    Patel, Manish R.
    Cho, Byoung Chul
    Liu, Stephen, V
    Ahn, Myung-Ju
    Chiu, Chao-Hua
    Lin, Jessica J.
    Goto, Koichi
    Lee, Jeeyun
    Bazhenova, Lyudmila
    John, Thomas
    Fakih, Marwan
    Chawla, Sant P.
    Dziadziuszko, Rafal
    Seto, Takashi
    Heinzmann, Sebastian
    Pitcher, Bethany
    Chen, David
    Wilson, Timothy R.
    Rolfo, Christian
    CLINICAL CANCER RESEARCH, 2022, 28 (10) : 2196 - 2196
  • [10] Entrectinib in Japanese patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
    Murakami, H.
    Ohe, Y.
    Hayashi, H.
    Esaki, T.
    Yamaguchi, T.
    Fukuhara, T.
    Daga, H.
    Tanaka, H.
    Kozuki, T.
    Osborne, S.
    Bordogna, W.
    Goto, K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1594 - S1594
12345